Q1 2025 Lantheus Holdings Inc Earnings Call Transcript
Key Points
- Lantheus Holdings Inc (LNTH) announced two strategic acquisitions, Evergreen Theragnostics and Life Molecular Imaging, to enhance their radiopharmaceutical leadership and sustain long-term growth.
- The company plans to divest its SPECT business to SHINE Technologies, streamlining operations and focusing on PET radiodiagnostics and radiotherapeutic agents.
- PYLARIFY sales reached $258 million in the first quarter, with strategic partnerships securing the majority of revenue.
- The company has a strong cash position and disciplined capital allocation strategy, enabling continued investment in capabilities and pipeline expansion.
- Lantheus Holdings Inc (LNTH) anticipates significant growth in the Alzheimer's radiodiagnostic market, with a potential total addressable market of $1.5 billion by the end of the decade.
- PYLARIFY experienced a low single-digit decline in net price, and competitive pressures are expected to continue impacting smaller non-contracted sites.
- Gross profit margin decreased by 180 basis points due to strategic partnership contracting initiatives and a moly supply shortage.
- Operating expenses increased, reflecting investments in growth and efficiency initiatives, impacting the company's profitability.
- The divestiture of the SPECT business, while strategic, will result in the loss of a stable revenue contributor.
- The company's guidance for adjusted EPS was lowered due to updated expectations for PYLARIFY performance and increased R&D investments.
Good morning. Welcome to Lantheus' first-quarter 2025 conference call. (Operator Instructions) I'll now turn the call over to Mark Kinarney, Vice President of Investor Relations. Mark?
Thank you. Good morning. With me today are Brian Markison, our CEO; Paul Blanchfield, our President; Bob Marshall, our CFO; and Amanda Morgan, our Chief Commercial Officer. We will begin with prepared remarks and then take your questions.
This morning, we issued a press release which was furnished to the SEC under Form 8-K reporting our first quarter 2025 results. The release and today's slide presentation are available in the Investors section of our website.
Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
